RTRX - Retrophin, Inc.

Retrophin, Inc. (RTRX) is a biopharmaceutical company that focuses on the development of treatments for rare diseases. The company is based in San Diego, California, and was founded in 2011.

As of market close on March 4th, 2023, the current market capitalization of RTRX was approximately $539.35 million.

Retrophin's product portfolio includes a range of treatments for rare diseases, including neurologic and metabolic disorders. The company's lead product, Chenodal, is used to dissolve gallstones in patients with gallbladder disease. Retrophin also has a pipeline of products in development, with a focus on rare diseases where there are unmet medical needs.

The company has faced challenges in recent years due to the high costs of drug development and the competitive landscape of the biopharmaceutical industry. However, Retrophin has worked to diversify its revenue streams and expand its product offerings through strategic acquisitions and partnerships.

Overall, Retrophin is a company that is focused on developing innovative treatments for rare diseases. While the company has faced challenges in a competitive and rapidly evolving industry, it has shown resilience and adaptability in continuing to pursue its mission to help patients with unmet medical needs.